People
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
In its announcement, the company did not specify why Kawas’ doctoral research was under investigation, only saying it did not intend to comment on the issue until it had been resolved.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.
Aaron Kesselheim, a professor of Medicine at Harvard Medical School and has served on the advisory committee since 2015, has stepped down.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Two of the company’s largest shareholders call for the ouster of a company director at Regeneron as top executives are under fire for their enormous compensation packages.
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
John Edwards, newly-appointed CEO of Verseau Therapeutics, is continually searching for something special.
PRESS RELEASES